Aliskiren + Hydrochlorothiazide + Amlodipine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Essential Hypertension ( Mild to Moderate)
Conditions
Essential Hypertension ( Mild to Moderate)
Trial Timeline
Sep 1, 2008 → Aug 1, 2009
NCT ID
NCT00765947About Aliskiren + Hydrochlorothiazide + Amlodipine
Aliskiren + Hydrochlorothiazide + Amlodipine is a approved stage product being developed by Novartis for Essential Hypertension ( Mild to Moderate). The current trial status is completed. This product is registered under clinical trial identifier NCT00765947. Target conditions include Essential Hypertension ( Mild to Moderate).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00765947 | Approved | Completed |
Competing Products
20 competing products in Essential Hypertension ( Mild to Moderate)